BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer

Mingzhao Xing, Douglas Clark, Haixia Guan, Meiju Ji, Alan Dackiw, Kathryn A. Carson, Matthew Kim, Anthony Tufaro, Paul Ladenson, Martha Zeiger, Ralph Tufano

Research output: Contribution to journalArticle

202 Citations (Scopus)

Abstract

Purpose: This study investigated the utility of BRAF mutation testing of thyroid fine-needle aspiration biopsy (FNAB) specimens for preoperative risk stratification in papillary thyroid cancer (PTC). Patients and Methods: We assessed the T1799A BRAF mutation status in thyroid FNAB specimens obtained from 190 patients before thyroidectomy for PTC and its association with clinicopathologic characteristics of the tumor revealed postoperatively. Results: We observed a significant association of BRAF mutation in preoperative FNAB specimens with poorer clinicopathologic outcomes of PTC. In comparison with the wild-type allele, BRAF mutation strongly predicted extrathyroidal extension (23% v 11%; P = .039), thyroid capsular invasion (29% v 16%; P = .045), and lymph node metastasis (38% v 18%; P = .002). During a median follow-up of 3 years (range, 0.6 to 10 years), PTC persistence/recurrence was seen in 36% of BRAF mutation-positive patients versus 12% of BRAF mutation-negative patients, with an odds ratio of 4.16 (95% CI, 1.70 to 10.17; P = .002). The positive and negative predictive values for preoperative FNAB-detected BRAF mutation to predict PTC persistence/recurrence were 36% and 88% for overall PTC and 34% and 92% for conventional PTC, respectively. Conclusion: Preoperative BRAF mutation testing of FNAB specimens provides a novel tool to preoperatively identify PTC patients at higher risk for extensive disease (extrathyroidal extension and lymph node metastases) and those who are more likely to manifest disease persistence/recurrence. BRAF mutation, as a powerful risk prognostic marker, may therefore be useful in appropriately tailoring the initial surgical extent for patients with PTC.

Original languageEnglish (US)
Pages (from-to)2977-2982
Number of pages6
JournalJournal of Clinical Oncology
Volume27
Issue number18
DOIs
StatePublished - Jun 20 2009

Fingerprint

Fine Needle Biopsy
Thyroid Gland
Mutation
Recurrence
Lymph Nodes
Neoplasm Metastasis
Papillary Thyroid cancer
Thyroidectomy
Alleles
Odds Ratio

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. / Xing, Mingzhao; Clark, Douglas; Guan, Haixia; Ji, Meiju; Dackiw, Alan; Carson, Kathryn A.; Kim, Matthew; Tufaro, Anthony; Ladenson, Paul; Zeiger, Martha; Tufano, Ralph.

In: Journal of Clinical Oncology, Vol. 27, No. 18, 20.06.2009, p. 2977-2982.

Research output: Contribution to journalArticle

Xing, M, Clark, D, Guan, H, Ji, M, Dackiw, A, Carson, KA, Kim, M, Tufaro, A, Ladenson, P, Zeiger, M & Tufano, R 2009, 'BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer', Journal of Clinical Oncology, vol. 27, no. 18, pp. 2977-2982. https://doi.org/10.1200/JCO.2008.20.1426
Xing, Mingzhao ; Clark, Douglas ; Guan, Haixia ; Ji, Meiju ; Dackiw, Alan ; Carson, Kathryn A. ; Kim, Matthew ; Tufaro, Anthony ; Ladenson, Paul ; Zeiger, Martha ; Tufano, Ralph. / BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 18. pp. 2977-2982.
@article{9ef43c1339a6457bb10da98c3ad081a3,
title = "BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer",
abstract = "Purpose: This study investigated the utility of BRAF mutation testing of thyroid fine-needle aspiration biopsy (FNAB) specimens for preoperative risk stratification in papillary thyroid cancer (PTC). Patients and Methods: We assessed the T1799A BRAF mutation status in thyroid FNAB specimens obtained from 190 patients before thyroidectomy for PTC and its association with clinicopathologic characteristics of the tumor revealed postoperatively. Results: We observed a significant association of BRAF mutation in preoperative FNAB specimens with poorer clinicopathologic outcomes of PTC. In comparison with the wild-type allele, BRAF mutation strongly predicted extrathyroidal extension (23{\%} v 11{\%}; P = .039), thyroid capsular invasion (29{\%} v 16{\%}; P = .045), and lymph node metastasis (38{\%} v 18{\%}; P = .002). During a median follow-up of 3 years (range, 0.6 to 10 years), PTC persistence/recurrence was seen in 36{\%} of BRAF mutation-positive patients versus 12{\%} of BRAF mutation-negative patients, with an odds ratio of 4.16 (95{\%} CI, 1.70 to 10.17; P = .002). The positive and negative predictive values for preoperative FNAB-detected BRAF mutation to predict PTC persistence/recurrence were 36{\%} and 88{\%} for overall PTC and 34{\%} and 92{\%} for conventional PTC, respectively. Conclusion: Preoperative BRAF mutation testing of FNAB specimens provides a novel tool to preoperatively identify PTC patients at higher risk for extensive disease (extrathyroidal extension and lymph node metastases) and those who are more likely to manifest disease persistence/recurrence. BRAF mutation, as a powerful risk prognostic marker, may therefore be useful in appropriately tailoring the initial surgical extent for patients with PTC.",
author = "Mingzhao Xing and Douglas Clark and Haixia Guan and Meiju Ji and Alan Dackiw and Carson, {Kathryn A.} and Matthew Kim and Anthony Tufaro and Paul Ladenson and Martha Zeiger and Ralph Tufano",
year = "2009",
month = "6",
day = "20",
doi = "10.1200/JCO.2008.20.1426",
language = "English (US)",
volume = "27",
pages = "2977--2982",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer

AU - Xing, Mingzhao

AU - Clark, Douglas

AU - Guan, Haixia

AU - Ji, Meiju

AU - Dackiw, Alan

AU - Carson, Kathryn A.

AU - Kim, Matthew

AU - Tufaro, Anthony

AU - Ladenson, Paul

AU - Zeiger, Martha

AU - Tufano, Ralph

PY - 2009/6/20

Y1 - 2009/6/20

N2 - Purpose: This study investigated the utility of BRAF mutation testing of thyroid fine-needle aspiration biopsy (FNAB) specimens for preoperative risk stratification in papillary thyroid cancer (PTC). Patients and Methods: We assessed the T1799A BRAF mutation status in thyroid FNAB specimens obtained from 190 patients before thyroidectomy for PTC and its association with clinicopathologic characteristics of the tumor revealed postoperatively. Results: We observed a significant association of BRAF mutation in preoperative FNAB specimens with poorer clinicopathologic outcomes of PTC. In comparison with the wild-type allele, BRAF mutation strongly predicted extrathyroidal extension (23% v 11%; P = .039), thyroid capsular invasion (29% v 16%; P = .045), and lymph node metastasis (38% v 18%; P = .002). During a median follow-up of 3 years (range, 0.6 to 10 years), PTC persistence/recurrence was seen in 36% of BRAF mutation-positive patients versus 12% of BRAF mutation-negative patients, with an odds ratio of 4.16 (95% CI, 1.70 to 10.17; P = .002). The positive and negative predictive values for preoperative FNAB-detected BRAF mutation to predict PTC persistence/recurrence were 36% and 88% for overall PTC and 34% and 92% for conventional PTC, respectively. Conclusion: Preoperative BRAF mutation testing of FNAB specimens provides a novel tool to preoperatively identify PTC patients at higher risk for extensive disease (extrathyroidal extension and lymph node metastases) and those who are more likely to manifest disease persistence/recurrence. BRAF mutation, as a powerful risk prognostic marker, may therefore be useful in appropriately tailoring the initial surgical extent for patients with PTC.

AB - Purpose: This study investigated the utility of BRAF mutation testing of thyroid fine-needle aspiration biopsy (FNAB) specimens for preoperative risk stratification in papillary thyroid cancer (PTC). Patients and Methods: We assessed the T1799A BRAF mutation status in thyroid FNAB specimens obtained from 190 patients before thyroidectomy for PTC and its association with clinicopathologic characteristics of the tumor revealed postoperatively. Results: We observed a significant association of BRAF mutation in preoperative FNAB specimens with poorer clinicopathologic outcomes of PTC. In comparison with the wild-type allele, BRAF mutation strongly predicted extrathyroidal extension (23% v 11%; P = .039), thyroid capsular invasion (29% v 16%; P = .045), and lymph node metastasis (38% v 18%; P = .002). During a median follow-up of 3 years (range, 0.6 to 10 years), PTC persistence/recurrence was seen in 36% of BRAF mutation-positive patients versus 12% of BRAF mutation-negative patients, with an odds ratio of 4.16 (95% CI, 1.70 to 10.17; P = .002). The positive and negative predictive values for preoperative FNAB-detected BRAF mutation to predict PTC persistence/recurrence were 36% and 88% for overall PTC and 34% and 92% for conventional PTC, respectively. Conclusion: Preoperative BRAF mutation testing of FNAB specimens provides a novel tool to preoperatively identify PTC patients at higher risk for extensive disease (extrathyroidal extension and lymph node metastases) and those who are more likely to manifest disease persistence/recurrence. BRAF mutation, as a powerful risk prognostic marker, may therefore be useful in appropriately tailoring the initial surgical extent for patients with PTC.

UR - http://www.scopus.com/inward/record.url?scp=67649970928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649970928&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.20.1426

DO - 10.1200/JCO.2008.20.1426

M3 - Article

C2 - 19414674

AN - SCOPUS:67649970928

VL - 27

SP - 2977

EP - 2982

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -